Known brand names include Singulair.
A once-daily oral leukotriene blocker. It is used for long-term asthma control, to prevent exercise-induced bronchoconstriction, and for allergic rhinitis when other treatments fail or are not tolerated. It does not treat an acute asthma attack.
The label does not describe a narrow therapeutic index or direct dosing by measured blood levels of the drug.
Sources: [1]
Serious neuropsychiatric events, including agitation, aggression, depression, sleep disturbances, and suicidal thoughts and behavior, including suicide. Benefits may not outweigh risks when symptoms are mild; reserve for allergic rhinitis that has not responded to or tolerated other therapies. Teach patients and caregivers to watch for behavior changes and to stop the drug and call a provider right away if they occur.
Sources: [1]
No specific antidote. Use usual supportive measures, such as removing unabsorbed drug, clinical monitoring, and supportive therapy. Whether dialysis removes montelukast is unknown.
Sources: [1]
Doses come from the FDA label. Study tool, not for clinical decisions.
Binds selectively to the cysteinyl leukotriene type 1 (CysLT1) receptor in the airways and on inflammatory cells and blocks leukotriene D4, with no agonist activity. This reduces leukotriene-driven airway edema, smooth muscle contraction, and inflammation in asthma and allergic rhinitis. It is metabolized mainly by CYP2C8, with CYP3A4 and 2C9.